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ABSTRACT
D-2-hydroxyglutarate (D-2HG) is released by various types of malignant cells including acute myeloid
leukemia (AML) blasts carrying isocitrate dehydrogenase (IDH) gain-of-function mutations. D-2HG acting
as an oncometabolite promotes proliferation, anoikis, and differentiation block of hematopoietic cells in
an autocrine fashion. However, prognostic impact of IDH mutations and high D-2HG levels remains
controversial and might depend on the overall mutational context. An increasing number of studies focus
on the permissive environment created by AML blasts to promote immune evasion. Impact of D-2HG on
immune cells remains incompletely understood. Here, we sought out to investigate the effects of D-2HG
on T-cells as key mediators of anti-AML immunity. D-2HG was efﬁciently taken up by T-cells in vitro, which
is in line with high 2-HG levels measured in T-cells isolated from AML patients carrying IDH mutations. T-
cell activation was slightly impacted by D-2HG. However, D-2HG triggered HIF-1a protein destabilization
resulting in metabolic skewing towards oxidative phosphorylation, increased regulatory T-cell (Treg)
frequency, and reduced T helper 17 (Th17) polarization. Our data suggest for the ﬁrst time that D-2HG
might contribute to ﬁne tuning of immune responses.
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Introduction
The oncometabolite alpha-hydroxyglutaric acid (2-hydroxyglu-
tarate, 2HG) has attracted increasing interest in recent years.
Monoallelic point mutations in the enzyme isocitrate dehydro-
genase (IDH), which occur amongst others in gliomas,1 glio-
blastoma,2 and acute myeloid leukemia (AML),3 lead to a loss-
of-function regarding conversion of isocitrate to a-ketoglutarate
(aKG) and a gain-of-function in terms of reducing aKG to the
D-enantiomer of 2HG (D-2HG).4,5 Several studies have aimed
to delineate the (autocrine) effects of D-2HG on tumor cells. It
has been shown that D-2HG is a competitive inhibitor of
aKG-dependent dioxygenases (such as histone demethylases
and the TET family of 5 mC hydroxylases) and its accumula-
tion leads to profound epigenetic alterations6 interfering with
hematopoietic differentiation.7 In fact, D-2HG is sufﬁcient to
promote leukemogenesis with the D-2HG-mediated transfor-
mation being reversible.7-9 D-2HG abundance has also been
linked to changes in the cellular redox equilibrium yielding an
increased reactive oxygen species (ROS) production, with oxi-
dative stress being one of the hallmarks of cancer.10 In addition
to redox metabolism, bioenergetic pathways also appear to be
potential D-2HG targets: introducing mutant IDH and exoge-
nous cell-permeable D-2HG application both promote
glutamine metabolism in colorectal cancer cells.11 Moreover,
D-2HG has been shown to diminish mitochondrial respiration
and respiration-coupled ATP production in glioblastoma
cells.12,13 While most studies are focusing on tumor-directed D-
2HG effects, its microenvironmental impact and, in particular,
its role in AML-mediated immune modulation remains unex-
plored. To date, a number of immune escape mechanisms have
been identiﬁed in AML and include depletion of (for activated
T-cells) critical nutrients such as tryptophan14 and/or the abun-
dant production of immune regulatory metabolites such as
ROS.15 In fact, a recent study on gliomas suggested that
D-2HG impairs CD8C T-cell responses while using IDH inhibi-
tors improved intrinsic antitumor immunity and enhanced the
efﬁcacy of a peptide vaccination-based therapy.16 Accordingly,
immune cell inﬁltration has been generally found decreased in
mutant IDH gliomas as compared to their wild type counter-
parts. Another recent report demonstrated in a murine system
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that accumulation of endogenous D-2HG at physiological con-
centrations due to an enhanced transaminase activity led to a
preferable Th17 over Treg differentiation by epigenetic
interference.17
Therefore, we were interested whether D-2HG (that can
reach concentrations of 5–35 mmol/L in glioma tissue18 and
2 – 600 mmol/L in AML19 patients’ serum) holds potential
immune regulatory properties by interfering with T-cell func-
tion. Our analyses revealed that D-2HG is efﬁciently taken up
by T-cells. This is in accordance with our ﬁndings that D-2HG
levels can be more than 1000-fold enriched in T-cells from
patients with AML blasts that harbor mutant IDH as compared
to (a) healthy controls and to (b) AML patients with wild-type
IDH. Even at high D-2HG concentrations (of 20 mmol/L) via-
bility, proliferation, and IFNg production were not negatively
affected in T-cells. However, bioenergetics of activated T-cells
shifted away from aerobic glycolysis towards respiration, which
is at least partly explained by the observed D-2HG-triggered
hypoxia inducible factor-1a (HIF-1a) destabilization. In line
with previous ﬁndings that HIF-1a-dependent (aerobic) glycol-
ysis orchestrates differentiation of Th17 cells,20 we found a
reduced Th17 polarization in the presence of D-2HG. More-
over, and in agreement with previous ﬁndings that regulatory
T-cells (Tregs) rely on oxidative phosphorylation to meet their
energetic demands frequencies of Tregs were increased upon
D-2HG treatment. Taken together, we show for the ﬁrst time
that exogenous D-2HG has substantial immune metabolic
effects on T-cells, establishing a sound basis for further explor-
ing its role for tumor-associated immune modulation especially
in view of potential therapeutic strategies.
Results
D-2HG impacts T-cell signaling but not ﬁtness
Different types of malignant cells (including gliomas,21,22 AML,5
and breast cancer23) can abundantly produce and release D-2HG,
which is then found in patients’ sera or tumors more than 100-
fold increased.4,24,25 Thus, it is of particular interest whether
immune cells such as T-cells take up tumor-derived D-2HG.
Uptake of exogenously applied non-cell permeable D-2HG by
puriﬁed healthy control-derived T-cells undergoing activation
was evaluated using an enzymatic assay as previously described.26
Intracellular D-2HG levels were found to be increased in a dose-
dependent manner showing that T-cells have the ability to enrich
exogenous D-2HG (Fig. 1Ai). Furthermore, mass spectrometric
analysis revealed a signiﬁcantly and highly elevated content of
2HG in two out of seven cases of T-cells derived from AML
patients as compared to T-cells from healthy donors (HD)
(Fig. 1Aii). Notably, 2HG levels were increased in T-cells from
AML patients carrying an IDH2 mutation (which represent
approx. 10–30% of all AML patients). This ﬁnding corroborates
the biological relevance of our in vitromodel.
Previously, it has been shown that intracellular D-2HG can
inﬂuence proliferation23 and viability27 of tumor cells. Hence,
effects of D-2HG on proliferation were evaluated by means of
ﬂow cytometry of T-cells (Fig. 1B) as well as thymidine incorpo-
ration in CD4C and CD8C T-cell subsets (Supplemental Fig. 1),
and on survival by Annexin V/7-AAD staining (Fig. 1C). In fact,
we could not detect an impairment of T-cell proliferation or an
increase in cell death. However, T-cell receptor activation
was slightly but signiﬁcantly reduced in the presence of 20 mM
D-2HG as indicated by the reduction of CD3z chain expression
and Zap70 phosphorylation (Fig. 1D). Activation markers such
as CD25 and CD137 were downregulated, although statistical
signiﬁcance was only reached for CD25 expression (Fig. 1E).
However, a clear time- and dose-dependent effect of D-2HG on
T-cell receptor activation could not be observed (Supplemental
Fig. 2) unless doses reached toxic values (40 mM). As the
observed effects were rather small and transient, we postulate
that the general ﬁtness of in vitro cultured T-cells and their abil-
ity to respond towards activating stimuli are not impaired by the
presence of D-2HG. Nevertheless, there remains the possibility
that effects provoked by D-2HG might be subliminal and that
the downstream signaling might still be functional because it
reaches a sufﬁcient triggering threshold.
D-2HG enhances glucose uptake while skewing
bioenergetics away from aerobic glycolysis towards
respiration
Activation, function, and differentiation of T-cells are highly
dependent on their bioenergetic proﬁle as recently reviewed by
Palmer et al.28 Activated T-cells (like cancer cells) undergo a
metabolic switch from oxidative phosphorylation towards aero-
bic glycolysis to meet their energetic and biosynthetic demands
referred to as “Warburg effect”. Hence, interfering with the
T-cells’ metabolic framework can substantially impact their
function. In fact, a dehydrogenase that converts D-2HG to
aKG29 has been identiﬁed and could theoretically mediate
the entry of high amounts of tumor-derived D-2HG into the
T-cells’ tricarboxylic acid (TCA) cycle.
Analysis using ﬂuorescent glucose analogues showed an
increase in glucose-uptake when T-cells were activated in the
presence of 20 mM D-2HG (Fig. 2Ai-Aii). This effect was time-
and dose-dependent (Supplemental Fig. 3). Interestingly, when
D-2HG was washed out and T-cells were cultured for three
more days in D-2HG-free medium glucose-consumption
returned to initial levels (Fig. 2Aiii). At the same time, lactate
concentrations as a surrogate for aerobic glycolysis were signiﬁ-
cantly reduced in the culture medium (Fig. 2B), again in a time-
and dose-dependent manner (Supplemental Fig. 4). Surface
expression of glucose-transporters (GLUTs) was not affected
(Supplemental Fig. 5). Since elevation of the intracellular glucose
levels can promote global intracellular protein glycosylation,30
which regulates intracellular signaling,31 O-GlcNAcylation was
determined by ﬂow cytometry using an antibody speciﬁc for O-
linked N-acetylglucosamine (RL2). Activation of T-cells
increased global O-GlcNAcylation and additional D-2HG treat-
ment elevated it even further (Supplemental Fig. 6).
Next, we tested whether D-2HG treatment yields glucose-
dependency. Viability and proliferation of D-2HG-treated
T-cells compared to untreated counterparts were not affected
by glucose restriction or by pharmacologically blocking
the glycolytic key pacemaker molecule hexokinase-2 using
2-deoxyglucose (2DG) (Fig. 2Ci-ii, Supplemental Fig. 7). To
further elucidate metabolic changes caused by exogenous
D-2HG, real-time analyses of oxygen consumption rate
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(OCR, indicative for mitochondrial respiration) as well as of
extracellular acidiﬁcation rate (ECAR, indicative for aerobic
glycolysis) were performed using an extracellular ﬂux analyzer
(Fig. 3A). The sequential addition of inhibitors allowed the
calculation of several metabolic parameters as previously
detailed.32 Those analyses revealed signiﬁcantly increased
basal and maximal respiration (Fig. 3Aii) as well as an
enhanced ATP-production linked to respiration (Fig. 3Aiii)
upon D-2HG treatment. At the same time, the rate of basal
aerobic glycolysis and the capacity to further enhance glycoly-
sis were both signiﬁcantly reduced (Fig. 3Av-vi) as already
indicated by the decreased lactate levels measured in the
Figure 1. Uptake and inﬂuence of exogenous D-2HG on survival, proliferation, and activation of T-cells. A) The uptake of D-2HG, exogenously supplied at different con-
centrations to T-cell cultures (stimulated with anti-CD2/CD3/CD28 coated beads), was measured after an incubation time of 72 h by a colorimetric enzymatic assay (Ai,
n D 3). Additionally, intracellular total 2HG (D- and S-enantiomer) levels of T-cells isolated from healthy donors (HD) and AML patients (AML) were quantiﬁed by liquid
chromatography-mass spectrometry (Aii). Cells were furthermore analyzed regarding the effects on proliferation (B; n D 6), survival (C; n D 11), T-cell receptor signaling
(D; n D 4-7), and activation-related surface marker expression as measured by FACS (E; n D 10) upon D-2HG treatment. T-cells were either unstimulated (unstim, grey
bars) or stimulated without (0 mM, black) or with (orange) D-2HG at indicated concentrations. FACS plots show analyses from a representative experiment. The Western
Blot image shows two representative donors from a total of four.  p < 0.05;  p < 0.01; ns: not signiﬁcant; n.d.: not detected.
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supernatants (Fig. 2B). Overall, D-2HG promotes a metabolic
switch towards oxidative phosphorylation in activated T-cells
(Supplemental Fig. 8). Together with the elevated glucose
uptake this data suggests an increased glucose ﬂux into the
TCA cycle instead of aerobic glycolysis. Indeed, levels of two
TCA-intermediates aKG and citrate were signiﬁcantly
increased (Fig. 3B). Mitochondrial biogenesis was not
enhanced and mitochondria maintained their electrochemical
gradient (D~cM) as a surrogate marker for their ﬁtness and
coupling efﬁcacy (Supplemental Fig. 9). Furthermore, relative
gene expression of LDHA (the enzyme that metabolizes pyru-
vate to lactate) and PDK1 (the enzyme that blocks oxidative
decarboxylation of pyruvate thereby preventing its entry into
the TCA cycle) were signiﬁcantly downregulated, while other
metabolic genes remained mostly unaffected (Fig. 3C). The
only signiﬁcantly upregulated gene was GLS, which can
metabolize glutamine to glutamate to either replenish the
TCA cycle and/or the hexosamine biosynthesis pathway
enabling amongst others increased protein glycosylation.
Based on previous ﬁndings that D-2HG acts as a pro-oxi-
dant33 and that an increased respiration (Fig. 3A) can contrib-
ute to abundant mitochondrial ROS release34 we assessed
various redox parameters in D-2HG treated T-cells. Flow cyto-
metric analysis of total cellular ROS and mitochondrial super-
oxide levels by means of CellROX and MitoSOX reagents,
respectively, showed no differences between untreated and D-
2HG treated T-cells (Supplemental Fig. 10). Levels of surface
thiols and intracellular glutathione as the major non-enzymatic
cellular antioxidants together with the expression of a number
of enzymatic antioxidants were also not impacted by D-2HG
(Supplemental Figs. 11 and 12).
D-2HG has no impact on T-cell IFNg production and
senescence, but on Treg frequency
As previously reviewed28, T-cell metabolism is tightly intercon-
nected with differentiation and function. First, we evaluated the
impact of D-2HG on the T-cells’ IFNg production. Despite
reduced CD3z chain expression and Zap70 phosphorylation
(Fig. 1D) we observed constant levels of IFNg (Fig. 4A and
Supplemental Fig. 13). In line, D-2HG had no impact on IFNg
secretion by T-cells activated with allogeneic dendritic cells;
however, proliferation was slightly affected (Fig. 4B). Impact on
the CD4C to CD8C T-cell ratio and induction of senescence as
measured by the surface expression of CD28 (which would be
reduced) and CD57 (which would be increased) was not
observed (Fig. 4C). Cytotoxic potency as exempliﬁed by the
expression of TNFa and perforin in CD4C and CD8C T-cell
subsets was not altered either (Supplemental Fig. 14). Since
reduction of aerobic glycolysis accompanied by an increase in
oxidative phosphorylation has also been reported to favor regu-
latory T-cells (Tregs),35 we evaluated the impact of D-2HG on
their frequency. Indeed, D-2HG promoted the frequency of
CD25C CD127low FoxP3C naturally occurring-like Tregs
(Fig. 4D). Furthermore, T-cell subsets were deﬁned according
to Mahnke et al36 as CD45RO¡CCR7C (na€ıve),
CD45ROCCCR7C (central memory), and CD45ROCCCR7¡
(effector memory) cells in the respective CD4C and CD8C T-
Figure 2. Changes of glucose metabolism induced by exogenous D-2HG. A) The increase in glucose uptake induced by 20 mM D-2HG supplementation was measured by
ﬂow cytometry (FACS) using a ﬂuorescent glucose analog (6NBDG) in a time course (Ai, n D 5-11) or after 72 h (Aii, n D 15) of T-cell culture. D-2HG was subsequently
removed from the culture and glucose uptake levels measured again after 72 h (Aiii, 20 mM depr, green bar, n D 5). Each pair of values in panel ii represents T-cells iso-
lated from one particular donor under different culturing conditions. B) Lactate secretion into the cell culture supernatant as a surrogate for glycolysis was measured after
72 h (B, n D 10). C) To evaluate a putative glucose-dependency created by exogenous D-2HG application T-cells were analyzed in terms of their proliferative capacity in
presence of reduced glucose availability in the culture medium (Ci, n D 3), and of viability upon hexokinase-2 inhibition by 2DG (Cii, n D 3) after 72 h of culture. T-cells
were either unstimulated (unstim, grey) or stimulated without (0 mM, black) or with (20 mM, orange) D-2HG. FACS histograms show one representative analysis. 
p<0.05;  p<0.01;  p<0.001; ns: not signiﬁcant.
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cell compartment. Despite reports about the importance of oxi-
dative phosphorylation for T-cell memory formation37 we did
not detect any D2-HG induced changes in the frequencies of
na€ıve, central memory, and effector memory T-cells (Fig. 4E).
Accordingly, the relative expression levels of genes involved in
memory T-cell formation were not altered as well (Supplemen-
tal Fig. 15).
D-2HG activates mTOR signaling but destabilizes HIF-1a
resulting in diminished Th17 cell formation
As shown in previous publications, mTOR signaling holds a
key role in cellular metabolism. It regulates mitochondrial oxy-
gen consumption,38 glucose uptake,39 and nutrient utilization40
by governing expression and/or activity of metabolic
enzymes.41 In fact, mutant IDH-expressing cell lines showed
enhanced mTOR signaling.42 In line with the increased glucose
uptake and mitochondrial respiration we observed enhanced
mTOR signaling as suggested by the levels of phosphorylated
mTOR (Fig. 5Ai) and its downstream target 4EBP1
(Supplemental Fig. 16) while gene expression levels remained
unaltered (Supplemental Fig. 17i). Accordingly, we conﬁrmed a
previously reported D-2HG-triggered suppression of the DEP-
TOR protein expression that acts as an endogenous mTOR
inhibitor (Supplemental Fig. 17ii).42 Moreover, treating acti-
vated T-cells with 20 mM D-2HG led to a substantial mTOR
signaling-addiction. Blocking mTOR by rapamycin had a
stronger effect on D-2HG treated T-cells in terms of reducing
glucose uptake and diminishing proliferation as compared to
their untreated counterparts (Fig. 5Aii-iii).
The increased mTOR activity is also in line with the afore-
mentioned results on increased O-glycosylation (Supplemental
Fig. 6). The responsible enzyme O-GlcNAc transferase (OGT)
can be controlled by mTOR31 and both immunoﬂuorescence
and Western Blot analyses revealed an increase in OGT level
upon D-2HG treatment (Supplemental Fig. 18).
Increased mTOR activity was also shown to enhance HIF-1a
expression.43 However, mutated IDH and intracellular 2-HG
accumulation promote prolyl hydroxylase activity that targets
the HIF-1a protein stability.44 Treating T-cells with D-2HG
Figure 3. Bioenergetic modulation of T-cells by exogenous D-2HG. A) Mitochondrial respiration of T-cells cultured in the absence or presence of D-2HG for 72 h was ana-
lyzed in real-time using the Seahorse extracellular ﬂux analyzer. Oxygen consumption rate (OCR) was recorded (Ai) and respiratory parameters were calculated (Aii-iii)
after sequential addition of oligomycin, FCCP, and antimycin A/rotenone (nD 4). Likewise, extracellular acidiﬁcation rate (ECAR) was assessed (Aiv) and glycolytic parame-
ters were calculated (Av-vi) after sequential addition of glucose, oligomycin, and 2DG (n D 4). B) Intracellular concentrations of two representative intermediates of the
TCA cycle (a-ketoglutarate: aKG, n D 3 and citrate, n D 5) were enzymatically determined. C) The expression of key metabolic genes was quantiﬁed by real-time PCR
(n D 3-12). T-cells were either unstimulated (unstim, grey) or stimulated without (0 mM, black) or with (20 mM, orange) D-2HG.  p < 0.05;  p < 0.01;  p < 0.001;
 p < 0.0001.
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reduced HIF-1a protein levels in a time- and dose-dependent
manner (Fig. 5B). HIF-1a gene expression was not impacted
(Fig. 5Ci). The HIF-1a protein reduction was accompanied by
a diminished RORC and IL17A gene expression as well as IL-17
A secretion (Fig. 5Ci-ii and Supplemental Fig. 13), which are in
line with data linking the HIF-1a-aerobic glycolysis axis with
Th17 polarization.45 D1 Those effects were speciﬁc for the onco-
metabolic D-enantiomer and could not be reproduced with the
S-enantiomer of 2HG (Supplemental Fig. 19). Chemical induc-
tion of HIF-1a using the iron chelator 2,20-dipyridyl (DIP) pro-
moted the gene expression of IL17A and MYC (as another
target gene of HIF-1a) (Supplemental Fig. 20) and also restored
the IL-17A secretion in the presence of D-2HG (Fig. 5Cii).
Those ﬁndings are further corroborated by our observation
that D-2HG treatment reduced the frequency of Th17 cells
(Fig. 5Di) and also the IL-17 levels within the Th17 population
(Fig. 5Dii). Ultimately, comparing Th17 frequencies within
PBMCs from AML patients harboring IDH mutations with
wildtype AML counterparts revealed a signiﬁcantly reduced
fraction of IL-17C CD4 T-cells in the specimen from IDH-
mutated AML cases (Fig. 5E).
Discussion
Accumulation of the oncometabolite D-2HG in several tumor
entities including AML,4,18,23,25 and its prognostic impact23
have raised interest in elucidating its role in cancer develop-
ment and progression. To date, the vast majority of studies
have focused on the autocrine tumor-directed D-2HG effects.
D-2HG levels are found up to 100-fold increased in tumor cells
and patients’ sera and affect pleiotropically the oncogenic
potential by epigenetic alterations,6 enhanced proliferation and
Figure 4. Impact of exogenous D-2HG on T-cell function. A) IFNg secretion by anti- CD2/CD3/CD28 stimulated T-cells was determined by sandwich ELISA (n D 9). B)
Mixed lymphocyte reactions were performed to analyze T-cell function. Immature dendritic cells (iDC) were co-cultured with T-cells (lymph) with/without LPS in the
absence (0 mM) or presence (10 mM) of D-2HG. Both, the secretion of IFNg (left panel) and T-cell proliferation (right panel) were measured by sandwhich-ELISA and thy-
midine intake, respectively. C) The ratio of CD4C to CD8C T-cells as well as the surface expression of CD28 and CD57 were analyzed after 72 h of anti-CD2/CD3/CD28 stim-
ulation by ﬂow cytometry (FACS) to evaluate T-cell senescence (n D 3). D) The frequency of regulatory T-cells amongst pan T-cells after stimulation with anti-CD2/CD3/
CD28 for 72 h was determined by FACS (n D 9). E) Frequency of na€ıve (CD45RO¡CCR7C), central memory (CD45ROCCCR7C) and effector memory (CD45ROCCCR7¡) T-
cell subsets of CD4C (left) and CD8C (right) T-cells stimulated for 72 h with and without anti-CD2/CD3/CD28 were measured by FACS (n D 3). T-cells were either unstimu-
lated (unstim, grey) or stimulated without (0 mM, black) or with (orange) D-2HG at indicated concentrations.  p<0.05;  p<0.01.
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differentiation arrest,8 preferential glutamine utilization,11,23
abundant ROS production,10 interference with mitochondrial
metabolism,12,13 and mTOR signaling.42 However, little is
known about the effects of D-2HG in shaping the microenvi-
ronmental immune components. In fact, tumor cells can alter
immune responses by depleting nutrients critical for immune
cells such as tryptophan14 and/or by abundantly releasing
immune regulatory metabolic byproducts such as lactic acid.46
Recent studies suggest (at least indirectly) that D-2HG affects
T-cells since IDH mutations were associated with a rather lim-
ited intratumoral T-cell inﬁltration.16,47 In fact, treating healthy
donor-derived T-cells with D-2HG leads to its intracellular
accumulation, although it is non-cell permeable and its mode
of transport remains elusive. The biological relevance of this
observation is further underlined by the fact that we report for
the ﬁrst time increased D-2HG levels in T-cells isolated from
AML patients harboring IDH2 mutations. No negative effects
on T-cell viability, proliferation, cytotoxic capacity, and IFNg
secretion were observed, which is in contrast to recent ﬁndings
about the impact of physiologically low levels of the S-enantio-
mer (S-2HG) on murine CD8C T-cells under hypoxia upon
TCR stimulation showing a decrease in effector cytokine secre-
tion and cell expansion.48 However, a transient reduction of
TCR downstream signaling intensity as exempliﬁed by reduced
CD3z and CD25 expression and lower Zap70 phosphorylation
levels could be documented. It is likely that the D-2HG-
induced effects on TCR signaling are not strong enough to pre-
vent an effective downstream signaling and, thus, still allow
achieving a sufﬁcient threshold that triggers e.g. effector cyto-
kine production. Moreover, the observed reduction of T-cell
proliferation in MLR in the presence of D-2HG cannot be
attributed to a direct inﬂuence but may also be indirectly medi-
ated by affecting the dendritic cells.
To date, it is well established that the so-called metabolic
signaling holds a key role in governing most aspects of T-cell
biology.28,49,50 Activated T-cells undergo metabolic reprogram-
ming that involves the rapid induction of aerobic glycolysis and
anabolic reactions. This initial metabolic transition towards
Figure 5. Inﬂuence of exogenous D-2HG on mTOR activation, HIF-1a protein stability and resulting Th17 formation. A) Activation of the mTOR signaling pathway (Ai; n D
6) as a function of the level of mTOR phosphorylation (p-mTOR) and the impact of mTOR inhibition by rapamycin on glucose uptake (Aii; n D 4) and T-cell proliferation
(Aiii; nD 3) upon D-2HG treatment were measured by ﬂow cytometry (FACS). Each pair of values in panel i represents T-cells isolated from one particular donor under dif-
ferent culture conditions. B) In addition, HIF-1a protein expression levels were analyzed by FACS showing one representative FACS analysis after 72 h (upper panel) and
the averages of repeated measures in a time-course (n D 3, lower panel). C) Relative gene expression of HIF1A, RORC, and IL17A (Ci, n D 8-23) and IL-17A secretion (Cii, n
D 5-10) by in vitro cultured T-cells treated for 24 h with D-2HG were measured by quantitative real-time PCR and sandwich-ELISA, respectively. In addition, IL-17 secretion
was measured in the presence of the hypoxia mimetic DIP that stabilizes HIF-1a (green bar). D) Anti-CD2/CD3/CD28 stimulated T-cells were restimulated after 72 h of cul-
ture with PMA/Ionomycin in the presence of GolgiPlugTM for 4 h and analyzed for the Th17 frequency (i, n D 8) and the intracellular IL-17 A content (ii, n D 8). E) Finally,
PBMCs from AML patients without (wt) and with IDH mutation (IDH mut) were compared by ﬂow cytometry for their Th17 frequency after 4 h of in vitro stimulation with
PMA/Ionomycin in the presence of GolgiPlugTM (n D 3-7). T-cells were either unstimulated (unstim) or stimulated in the absence (0 mM, black) or presence (orange) of D-
2HG at the given concentrations. FACS histograms show one representative analysis.  p<0.05;  p<0.01;  p<0.001;  p<0.0001; ns: not signiﬁcant.
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aerobic glycolysis is strongly associated with the mTOR path-
way. In fact, abundant D-2HG production has been reported to
promote a PI3K/AKT-independent mTOR activation.42 One of
the proposed and by us conﬁrmed underlying mechanisms is a
D-2HG-mediated reduction of the endogenous negative regula-
tor of mTOR activity called DEPTOR.42,51,52 We observed
enhanced levels of mTOR phosphorylation (with unaltered
MTOR gene expression together with DEPTOR protein reduc-
tion) upon D-2HG application that were accompanied by
numerous known downstream phenomena including increased
glucose inﬂux,39 glycosylation,31 and mitochondrial respira-
tion.38 Despite enhanced glucose uptake aerobic glycolysis rate
was found decreased leading to an overall metabolic skewing
towards oxidative phosphorylation suggesting that the glucose
ﬂux is mainly fueling the TCA cycle. In fact and in line with
this rationale, we found increased levels of TCA cycle inter-
mediates (i.e. aKG and citrate) in D-2HG treated T-cells while
expression of pyruvate dehydrogenase kinase 1 (PDK1) that
blocks the entry of pyruvate into the TCA cycle was downregu-
lated. Moreover, the TCA cycle could also be additionally
replenished by an anaplerotic conversion of the abundant D-
2HG to aKG by D-2HG dehydrogenase,53 which obviously
requires further elucidation. Likewise, an anaplerosis of the
TCA cycle might occur via glutaminolysis as seen by the signiﬁ-
cant induction of glutaminase (GLS) by D-2HG treatment.
However, T-cells cultured in glutamine-free medium did not
show any additional impairments in terms of viability and pro-
liferation upon D-2HG addition (data not shown). Thus, this
pathway seems to be dispensable in this context.
In addition to mTOR, metabolic transition towards aerobic
glycolysis (upon T-cell stimulation) is driven by HIF-1a that,
among other functions, regulates expression of LDHA and
PDK1.54-56 Indeed, we observed HIF-1a protein destabilization
upon D-2HG treatment and in line reduced LDHA and PDK1
expression following D-2HG uptake. In fact, earlier publica-
tions have shown that IDH mutations together with D-2HG
accumulation negatively impact HIF-1a stability by promoting
proteasomal degradation after activation of the HIF-1a speciﬁc
prolyl hydroxylases (EglNs) in malignant cells.8,44 Thus,
reduced HIF-1a signaling could contribute to the observed
metabolic shift away from aerobic glycolysis towards oxidative
phosphorylation despite substantial mTOR activation, which
otherwise would enhance HIF-1a transcriptional activity in
case HIF-1a protein is stably expressed.43 D2
As previously mentioned, metabolic signaling is tightly
linked to T-cell function and differentiation. Certain metabolic
proﬁles are linked to speciﬁc T-cell subsets. Regulatory T-cells
(Tregs) as well as memory T-cells have been shown to exhibit a
reduced glycolytic activity and to rely more on oxidative phos-
phorylation (and fatty acid oxidation), while effector T-cell
subsets meet their energetic demand by aerobic glycolysis.49
Thus, we reasoned that the D-2HG induced shift towards oxi-
dative phosphorylation might increase the frequency of Tregs
and/or memory T-cells. Indeed, we observed enhanced fre-
quencies of Tregs upon treatment with D-2HG suggesting an
additional link between neoplasia-derived D-2HG as a bioac-
tive metabolite and immune modulation. Still, it remains to be
elucidated whether enhanced respiratory capacity induced by
D-2HG uptake in T-cells increases Treg formation or if Treg
survival/persistence is simply favored by elevated levels of
tumor-derived D-2HG due to so far unexplored selection
mechanisms as seen e.g. for ROS57,58 or lactate.59 On the other
hand, we could not detect any changes in the formation of
memory T-cells. Furthermore, several studies also demon-
strated that an effective anti-tumor functionality of T-cells
within the tumor microenvironment is largely depending on
their glycolytic activity rather than oxidative phosphorylation
in vivo.60 Although we did not detect impairments of T-cell
cytotoxicity in our in vitro system, the inﬂuence of D-2HG via
metabolic interference on tumor eradication by T-cells in the
in vivo situation clearly has to be further examined (in preclini-
cal models). Additionally, enhanced oxidative phosphorylation
(caused by enhanced mitochondrial biogenesis and ﬁtness) was
also shown to increase the production of ROS34 which in turn
are amongst others important for a proper (antigen-speciﬁc) T-
cell activation61,62 as well as HIF-1a stabilization.63 However,
in our setup we could not detect any changes in neither total
cellular nor mitochondrial ROS levels upon D-2HG applica-
tion. Since ROS production is already induced by (anti-CD2/
CD3/CD28) TCR stimulation in vitro, D-2HG seems to be dis-
pensable for ROS-mediated functions/signaling in this setup.
Obviously, this needs to be further explored with in vivo
models.
Beyond that, binding of HIF-1a further enhances transcrip-
tion of Th17-speciﬁc genes and ﬁnally Th17 polarization. Con-
sequently, D-2HG-mediated HIF-1a destabilization led to
reduced expression of the prototypical Th17 transcription fac-
tor RORC as well as IL-17A secretion. Both phenomena were
restored by chemical stabilization of HIF-1a. Accordingly, D-
2HG numerically reduced Th17 cells that additionally showed
less IL-17 production (per cell) further strengthening the over-
all effect. Finally, upon stimulation the frequency of Th17 cells
in AML patient-derived samples was reduced in those having
AML clones with mutated IDH in contrast to their wildtype
counterparts supporting the biological relevance of our ﬁnd-
ings. Thus, D-2HG contributes to reduced expression of RORC
and IL-17 in T-cells thereby diminishing Th17 polarization.
However, the role of Th17 cells in AML prognosis and progres-
sion is still under debate.64-66 While some studies show
increased levels of Th17 cells in the peripheral blood of AML
patients being associated with poor prognosis,64,67 others dem-
onstrate a decreased frequency of Th17 cells and related cyto-
kines in newly diagnosed AML patients with an amelioration
of those differences upon chemotherapy.65,68 In addition, Th17
cells are known to be an important player in the clearing of
infections69 being one of the major causes of morbidity and
mortality in AML.70 Noteworthy, in contrast to our observa-
tions, a recent publication demonstrated a dysbalance between
Th17 and Treg cells in favor of Th17 cells driven by induced
2HG accumulation (via transaminase activity or application of
cell-permeable dimethyl-2HG) in a murine system of autoim-
munity.17 The differences might be explained by species-related
differences or the use of a cell-permeable dimethyl-2HG as an
exogenous supply in contrast to the here used non-permeable
D-2HG disodium salt.
Taken together, our data suggests that abundantly produced
D-2HG in tumors that harbor IDH mutations such as AML
and glioma may act (in addition to its oncometabolic potential)
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as a novel immunometabolic modulator. The T-cells’ bioener-
getics are shifted towards oxidative phosphorylation and inter-
ference with the stability of the pro-glycolytic HIF-1a
diminishes the formation of pro-inﬂammatory Th17 cells and
favors the abundance of Tregs. Self-evidently, more studies on
the D-2-HG’s impact on the various components of the
patient’s immune system will be necessary in order to put our
observation into the context of both anti-tumor immunity as
well as protection from infections that are major causes of mor-
tality and morbidity during disease progression.
Materials and methods
Patient material
Peripheral blood mononuclear cells (PBMCs) from both AML
patients and healthy donors (HD) were collected upon approval
by the local ethics committee (approval number: 219_14B) and
participants’ written informed consent in accordance with the
Declaration of Helsinki.
Antibodies and primers
Antibodies and primers were purchased and used according to
the tables 1–4 in supplemental information.
Cell culture
T-cells were isolated from healthy donor-derived human
PBMCs using the Pan T-cell Isolation Kit (Miltenyi Biotec,
130-096-535) according to the manufacturer’s instructions.
Cells were cultured at a density of 1 £ 106/ mL in RPMI1640
(ThermoFisher Scientiﬁc, 31870074) supplemented with 2 mM
L-Glutamine (Sigma-Aldrich, G7513), 10% FCS (PAN Bio-
Tech, P30-3302) and 40 U/ mL Penicillin-Streptomycin (Ther-
moFisher Scientiﬁc, 15140122) for 72 h at 37C and 5% CO2
atmosphere if not stated otherwise. To stimulate the cells T-cell
activation/expansion beads coated with anti-CD2/CD3/CD28
(Miltenyi biotec, 130-091-441) at a bead:T-cell ratio of 1:2 were
used.
For restimulation of healthy donor-derived T-cells after 72 h
of culture in presence/absence of D-2HG, as well as for ex vivo
analysis of Th17 cells from AML PBMCs, cells were treated
with 50 ng/ mL PMA and 1 mg/ mL ionomycin in the presence
of GolgiPlugTM (as recommended by the manufacturer) for 4–
6 h at 37C and 5% CO2.
Flow cytometry
Proliferation was analyzed by staining T-cells with Violet Pro-
liferation Dye 450 (BD Bioscience, 562158) according to the
manufacturer’s instructions.
Cell death was determined by staining with Annexin V-
FITC (Biolegend, 640906) using the according buffer (Biole-
gend, 422201) in combination with 7AAD (Biolegend, 420404)
as described by the manufacturer.
All surface and intracellular stainings included a dead cell
exclusion using Zombie AquaDye (Biolegend, 423102). Cells
were washed in PBS and blocked with Human TruStain FcXTM
(Biolegend, 422302) and polyclonal mouse IgG (Dianova,
015-000-003) prior to the staining. Intracellular staining was
performed with a Fixation/Permeabilization Solution Kit (BD
Bioscience, 555028). Intranuclear staining was performed using
the Foxp3/Transcription Factor Staining Buffer Set (eBio-
science, 00-5523-00) according to the manufacturer’s instruc-
tions. Antibodies were incubated at the recommended
concentrations for 20 – 45 min at 4C.
Glucose uptake was analyzed using the ﬂuorescent glucose
analog 6-NBDG (ThermoFisher Scientiﬁc, N23106). Cells were
washed in PBS and glucose-free medium by centrifugation (300
x g, 6 min, 4C) and resuspended in 300 mL of glucose-free
medium containing 0.3 mM 6-NBDG. Samples were incubated
for 15 min at 37C, 5% CO2 and subsequently recorded after
two washing steps.
To analyze cellular redox-parameters, the anti-oxidative
capacity, and the mitochondrial biomass and ﬁtness CellROX
Deep Red Reagent (ThermoFisher Scientiﬁc, C10422) and
MitoSOXTM Red (ThermoFisher Scientiﬁc, M36008), Thio-
lTrackerTM Violet (ThermoFisher Scientiﬁc, T10095) and Alexa
Fluor 633 C5 Maleimide (ThermoFisher Scientiﬁc, A20342) as
well as MitoTracker Green (ThermoFisher Scientiﬁc, M7514)
and JC-1 (Cayman Chemicals, 10009172) were used respec-
tively according to the compounds’ manuals.
Extracellular ﬂux analysis
One day prior to measurements, Seahorse XFe96 culture
plates (Agilent/Seahorse Bioscience) were coated with
CorningTM Cell-Tak Cell and Tissue Adhesive (BD, 354241)
according to the manufacturer’s recommendations. A Sea-
horse XFe96 cartridge (Agilent/Seahorse Bioscience) was
loaded with XF Calibrant solution (Agilent/Seahorse Biosci-
ence) and incubated overnight in a CO2-free atmosphere. The
next day, cells were harvested from the culture, washed in
assay-speciﬁc medium according to the manufacturer’s rec-
ommendations and viable cells were automatically counted
on a Muse Cell Analyzer (Merck Millipore). The cells were
seeded at a density of 2.4 £ 105 T-cells in 175 mL per well.
The ports of the Seahorse cartridge were loaded with 25 mL
each of 80 mM glucose, 9 mM oligomycin, and 1 M 2DG for
the glycolysis stress test and 20 mL of 10 mM oligomycin,
22 mL of 15 mM FCCP, and 25 mL of 30 mM antimycin A/
rotenone for the mitochondrial stress test. After sensor cali-
bration, assays were run as detailed in the manufacturer’s
manual by recording ECAR (extracellular acidiﬁcation rate)
and OCR (oxygen consumption rate). Metabolic parameters
were obtained from the XF Wave software (Agilent/Seahorse
Biosciences) and calculated using Microsoft Excel.
Statistics
Statistics were calculated with Graphpad Prism Version 7 (La
Jolla, California, USA). Comparisons between groups were per-
formed using the appropriate statistical methods depending on
Gaussian distribution and number of groups and variables, i.e.
one-way ANOVA with Tukey’s post-hoc test, two-way
ANOVA with Bonferroni post-hoc test, unpaired and paired
two-tailed t-test, and Mann-Whitney test.
ONCOIMMUNOLOGY e1445454-9
Abbreviations
2DG 2-deoxglucose
aKG a-ketoglutarate
D-2HG D-2-hydroxyglutarate
DIP 2’2-dipyridyl
ECAR extracellular acidiﬁcation rate
GLUT glucose transporter
HD healthy donor
HIF-1a hypoxia inducible factor-1a
OCR oxygen consumption rate
OGT O-linked N-acetylglucosamine (GlcNAc) transferase
ROS reactive oxygen species
TCA tricarboxylic acid
Treg regulatory T-cell
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